Xerion’s technology improves the effectiveness of conventional radiotherapy while minimising side-effects. The company’s Oxilia nanoparticles have a physical mode of action and offer the ability to improve treatment of a wide range of solid tumours.
A strong background, a strong future
Spun out from Oxford University in 2015 following eight years of research, Xerion Healthcare is based and founded in the UK to develop and commercialise Oxilia treatment.
- Oxilia has a physical mode of action and Best-in-class radio sensitiser delivering unparalleled dose enhancement of radiotherapy
- Targeting a wide range of poorly treated solid tumours – initial focus on head & neck cancer
- Regulated as a class III medical device
Strong IP position
- Granted patents: EU, US, China, Japan
- Patent protection to 2037
- Clear freedom-to-operate position
- Extensive manufacturing know-how
The Xerion Team
Xerion’s management team has extensive commercial experience combined with pioneering nanotechnology expertise and support from world-leading oncologists.
Ian George, NED
Tech investor, extensive experience in developing & raising funds for healthcare companies
Xerion is founded to bring Oxilia to market, based on patent filed in 2010
Xerion files patent to expand the scope of technology and its applications
August 2015 - Seed investment from New Wave Ventures & Parkwalk Advisors
Innovate UK Biomedical Catalyst early stage grant awarded
Xerion’s technology efficacy and safety demonstrated in vivo
December 2017 - Investment from Oxford Sciences Innovation
Innovate UK Biomedical catalyst feasibility grant awarded
April 2018 - Prof Justin Stebbing appointed to company Chair
September - Innovate UK Biomedical Catalyst late stage grant awarded to support product scale-up & pre-clinical testing